Table 2. Genotypic–phenotypic associations in SLE.

Gene (clinical manifestation)	Meta-analysis					European-derived		Hispanic		African-American		Asian
	N	p Value*	OR (95% CI)	pBonferroni	pheter	padmix	OR (95%CI)	padmix	OR (95% CI)	padmix	OR (95% CI)	padmix	OR (95% CI)
FCGR2A (malar rash)	4	0.0031	1.11 (1.17 to 1.33)	0.049	0.54	0.011	1.14 (1.03 to 1.27)	0.15	1.11 (0.96 to 1.30)	0.90	1.01 (0.88 to 1.16)	0.12	1.16 (0.96 to 1.39)
ITGAM (discoid rash)	3	0.0020	1.20 (1.06 to 1.33)	0.031	0.79	0.033	1.18 (1.01 to 1.39)	0.066	1.31 (0.98 to 1.75)	0.14	1.17 (0.95 to 1.43)	NA	NA
STAT4 (oral ulcers)	4	0.0027	0.89 (0.83 to 0.96)	0.042	0.94	0.066	0.9 (0.81 to 1.01)	0.060	0.86 (0.74 to 1.01)	0.21	0.88 (0.72 to 1.07)	0.32	0.9 (0.78 to 1.09)
ITGAM (renal disorder)	3	5.0×10−6	1.25 (1.12 to 1.35)	7.99×10−5	0.050	4.7×10−7	1.39 (1.22 to 1.58)	0.41	1.09 (0.89 to 1.34)	0.37	1.09 (0.90 to 1.33)	NA	NA
TNFSF4 (renal disorder)	4	0.0013	1.14 (1.07 to 1.25)	0.020	0.50	0.0030	1.18 (1.06 to 1.33)	0.052	1.17 (1.00 to 1.37)	0.74	1.05 (0.80 to 1.38)	0.81	1.02 (0.85 to 1.22)
IL21 (haematological disorder)	4	0.0027	1.13 (1.04 to 1.22)	0.042	0.54	0.010	1.16 (1.03 to 1.30)	0.78	1.02 (0.86 to 1.22)	0.36	1.09 (0.91 to 1.30)	0.055	1.22 (1.00 to 1.50)

OR were calculated for risk alleles in each susceptibility genetic locus in systemic lupus erythematosus (SLE) comparing patients with and without the various clinical American College of Rheumatology SLE classification criteria. Only significant associations in the meta-analysis with a false discovery rate of less than 0.05 and that also pass the threshold for multiple testing by Bonferroni correction are depicted.

^*False discovery rate <0.05.

N, number of cohorts included in the meta-analysis; NA, not applicable; p_admix, p value adjusted for admixture; p_heter, heterogeneity p value.